Oxford BioMedica (OXB.L) Raised Its Forecast Of Total Revenue By The End Of 2021

The AstraZeneca deal appears to have been one of the main drivers of Oxford Biomedica’s rapid share price rise in 2020, helping to lift it from 673 GBP to 1,000 GBP by the end of the year. This growth has continued since then, and the stock has increased by more than 60% over the past 12 months. After AstraZeneca ordered more batches of the CAVID-19 vaccine from Oxford Biomedica in the second half of 2021, the company’s estimated revenue has more than doubled. In early trading, shares of the cell therapy business climbed 6.2 % after an agreement was reached on the mass manufacture of the AstraZeneca vaccine against COVID-19.

Oxford Biomedica increased its expectation of total revenue from AstraZeneca to more than 100 million pounds ($141.82 million) by the end of 2021, up from more than 50 million pounds previously. The business did not give any other information on the deal. The deal to increase supplies, according to Liberum analysts, is a “major affirmation” of Oxford Biomedica’s capabilities, and that future expansion is likely.

Paul Meyer

Part-Time Reporter. Paul could do better in his engineering profession where he became a real pro. However, he chose the finance field to find a tranquil environment in his career. Today he creates a good number of great content for our team.

Want Hot Stocks?    Yes. I Love Them No thanks